New insights into the biology of schizophrenia through the mechanism of action of clozapine

Neuropsychopharmacology

Volumn 13, Issue 3, 1995, Pages 177-213

  Brunello, Nicoletta ^a,b   Masotto, Claudio ^a   Steardo, Luca ^c   Markstein, Rudolf ^d   Racagni, Giorgio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d Preclinical Research   (Switzerland)

Author keywords

Atypical antipsychotic; Clozapine; Dopamine; Neuroleptic; Schizophrenia; Serotonin

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR;

BIOLOGY; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANIMAL; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; COMPARATIVE STUDY; DOPAMINE; HUMAN; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 0028785179     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00068-O     Document Type: Review

References (449)

1. Abercrombie ED, Zigmond MJ (1990): Striatal dopamine release: In vivo evidence for local initiation. Ann NY Acad Sci 604:575-578
2. Ackenheil M (1989): Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 99:S32-S37
3. Altar CA, Boyar WC, Wasley A, Gerhardt SG, Liebman JM, Wood WL (1988): Dopamine neurochemical profile of atypical antipsychotic resembles that of Di antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 338:162-168
4. Anden NE, Grenhoff J, Svensson TH (1988): Does treatment with haloperidol for 3 weeks produce depolarization block in midbrain dopamine neurons of unanesthetized rats? Psychopharmacology 96:558-560
5. Andersen PH (1988): Comparison of the pharmacological characteristics of 3H-raclopride and 3H-SCH23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146:113-120
6. Andersen PH, Braestrup C (1986): Evidence for different states of the dopamine Di receptor: Clozapine and fluper-lapine may preferentially label an adenylate cyclase-coupled state of the Di receptor. J Neurochem 47:1830-1831
7. Andersen PH, Nielsen EB, Gronvald FC, Braestrup C (1986): Some atypical neuroleptics inhibit [3H]SCH23390 binding in vivo. Eur J Pharmacol 120:143-144
8. Andreasen NC (1988): Brain imaging: Applications in psychiatry. Science 239:1381-1388
9. Arbilla S, Langer SZ (1984): Differential effects of the stereoisomers of 3-PPP on dopaminergic and cholinergic neurotransmission in superfused slices of the corpus striatum. Naunyn-Schmiedeberg's Arch Pharmacol 327: 6-13
10. Arnold SE, Hyman BT, Hoesen GWV, Damasio AR (1991a): Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 48:625-632
11. Arnold SE, Lee VM, Gur RE, Trojanowski JQ (1991b): Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subhelds of the hippocam-pal formation in schizophrenia. Proc Natl Acad Sci USA 88:10,850-10,854
12. Arora RC, Meltzer HY (1991): Serotonin 2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 85:19-29
13. Ashby B (1990): Dopamine and schizophrenia. Nature 348:493
14. Ashby CR, Wang RY (1990): Effects of antipsychotic drugs on 5-HT2 receptors in the medial prefrontal cortex: Microiontophoretic studies. Brain Res 506:346-348
15. Bacopoulos NG (1983): [3H]dopamine binds to Di and D2 receptors in rat striatum. Eur J Pharmacol 87:353-356
16. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993): Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9:117-124
17. Baldessarini RJ, Frankenburg FR (1991): Clozapine: A novel antipsychotic agent. New Engl J Med 324:746-754
18. Balsara JJ, Jadhav JH, Chandorkar AG (1979): Effect of drugs influencing central serotonergic mechanism on haloperi-dol-induced catalepsy. Psychopharmacology 62:67-69
19. Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL (1993): Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylyl cyclase. J Biol Chem 268:23,422-23,426
20. Beckmann H, Jakob H (1991): Prenatal disturbances of nerve cell migration in the entorhinal region: A common vulnerability factor in functional psychoses? J Neural Transm (Gen Sect) 84:155-164
21. Ben-Jonathan N, Olivier CH, Weiner HJ, Mical RS, Porter JC (1977): Dopamine in hypophyseal portal plasma of the rat during the oestrus cycle and throughout pregnancy. Endocrinology 100:452-456
22. Benes F, Sunderland P, Jones BD, LeMay M, Cohen BM, Lipinski JF (1982): Normal ventricles in young schizophrenics. Br J Psychiatry 141:90-93
23. Benes FM, Davidson J, Bird ED (1986): Quantitative cytoar-chitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 43:31-35
24. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL (1991): Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001
25. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP (1992): Increased GABA-A receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12:924-929
26. Bergeron R, Debonnel G, de Montigny C (1993): Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands. Eur J Pharmacol 240:319-323
27. Berkowitz BA (1974): Effects of the optical isomers of the narcotic antagonist analgesic pentazocine on brain and heart biogenic amines. Eur J Pharmacol 26:359-365
28. Berman KF, Randolph C, Gold J, Holt D, Jones DW, Goldberg TE, Carson RE, Herscovitch P, Weinberger DR (1991): Physiological activation of frontal lobe studies with positron emission tomography and oxygen-15 water during working memory tasks. J Cerebr Blood Flow Metab 11 (suppl. 2): 5851
29. Blaha CD, Lane RF (1987): Chronic treatment with classical and atypical antipsychotic drugs differentially decreases dopamine release in striatum and nucleus accumbens in vivo. Neurosci Lett 78:199-204
30. Blandina P, Goldfarb J, Green JP (1988): Activation of a 5-HT2 receptor releases dopamine from rat striatal slices. Eur J Pharmacol 155:349-350
31. Bleich A, Brown S, Kahn R, van Praag H (1988): The role of serotonin in schizophrenia. Schizophr Bull 14:297-315
32. Bogerts B, Ashtari M, Degreef G, Alvir JMJ, Bilder RM, Lie-berman JA (1990a): Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res 35:1-13
33. Bogerts B, Falkai P, Haupts M, Greve B, Ernst S, Tapernon-Franz U, Heinzmann U (1990b): Post mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics: Initial results from a new brain collection. Schizophr Res 3:295-301
34. Bogerts B, Meertz E, Schonfeldt-Bausch R (1985): Basal ganglia and limbic system pathology in schizophrenia. Arch Gen Psychiatry 42:784-791
35. Bolden C, Cusack B, Richelson E (1991): Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 192:205-206
36. Bolden C, Cusack B, Richelson E (1992): Antagonism by an-timuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260:576-580
37. Bolden-Watson C, Watson MA, Murray KD, Isackson PJ, Richelson E (1993): Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J Neurochem 61:1,141-1,143
38. Bondesson U, Lindstrom LH (1988): Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology 95:472-475
39. Booth RG, Baldessarini RJ (1991): (+)-6,7-benzomorphan sigma ligands stimulate dopamine synthesis in rat corpus striatum. Brain Res 557:349-352
40. Borison RL, Diamond BI, Pathiraja A, Meibach RC (1992): Clinical overview of risperidone. In Meltzer HY (ed), Novel Antipsychotic Drugs. New York, Raven Press, pp 233-239
41. Bormann J (1989): Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 66:591-592
42. 2 receptor mRNA. Brain Res 564:203-219
43. Bowen WD, Moses EL, Tolentino PJ, Walkers JM (1990): Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D2 receptors. Eur J Pharmacol 117:111-118
44. 2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol 131:301-306
45. Brown R, Colter N, Corsellis JAN, Crow TJ, Frith CD, Jagoe R, Johnstone EC (1986): Postmortem evidence of structural brain changes in schizophrenia. Differences in brain-weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry 43:36-42
46. Buerki DR, Ruch W, Asper H, Baggiolini M, Stille G (1974): Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat. Eur J Pharmacol 27:180-190
47. Bull DR, Sheehan MJ (1991): Presynaptic regulation of electrically evoked dopamine overflow in nucleus accumbens: A pharmacological study using fast cyclic voltammetry in vitro. Naunyn-Schmiedeberg's Arch Pharmacol 343:260-265
48. Bunney BS, DeRiemer S (1982): Effect of clonidine on dopaminergic neuronal activity in the substantia nigra: Possible indirect mediation by noradrenergic regulation of the serotonergic raphe system. In Friedhoff AJ, Chase TN (eds), Gilles de la Tourette Syndrome. New York, Raven Press, pp 99-104
49. Bunney BS, Grace AA (1978): Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sci 23:1,715-1,728
50. Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973): Dopaminergic systems: Effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 195:560-571
51. 2 dopamine receptor cDNA. Nature 336:783-787
52. Caldwell AE (1978): History of psychopharmacology. In Clark WG, Delgiudice J (eds), Principles of Psychopharmacology. New York, Academic Press, pp 9-40
53. 3-PPP and the PCP receptor-specific ligand TCP act in the mouse vas deferens via augmentation of electrically evoked norepinephrine release. Eur J Pharmacol 138:447-449
54. Canton H, Verriele L, Colpaert FC (1990): Binding of typical and atypical antipsychotics to 5HTlc and 5HT2 sites: Clozapine potently interacts with 5HTlc sites. Eur J Pharmacol 191:93-96
55. Carlsson A (1978): Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135:164-173
56. Carlsson A, Lindqvist M (1976): Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and nor-metanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144
57. Carlsson A, Svensson A, Carlsson ML (1993): Future strategies in the discovery of new antipsychotic agents: Focus on dopamine-glutamate interactions. In Brunello N, Mendlewicz J, Racagni G (eds), New Generation of Antipsychotic Drugs: Novel Mechanism of Action. Int Acad Biomed Drug Res vol. 4, Basel, Karger, pp 118-129
58. Carlsson M, Carlsson A (1990): Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276
59. Carrozza DP, Ferraro TN, Golden GT, Reyes PF, Hare TA (1992): In vivo modulation of excitatory amino acid receptors: Microdialysis studies on N-methyl-D-aspartate-evoked striatal dopamine release and effects of antagonists. Brain Res 574:42-48
60. Carter CJ, Pycock CJ (1977): Possible importance of 5-hydroxy-tryptamine in neuroleptic-induced catalepsy in rats. Br J Pharmacol 60:267-268
61. Carvey PM, Hitri A, Goetz CG, Tanner CM, Klawans HL (1993): Concurrent treatment with benztropine and haloperidol attenuates the development of behavioral hypersensitivity but not dopamine receptor proliferation. Life Sci 42:2,207-2,215
62. Carvey PM, Nath ST, Kao LC, Zhang TJ, Lin DH, Singh R, Amdur RL, Klawans HL (1990): Clozapine fails to prevent the development of haloperidol-induced behavioral hypersensitivity in a cotreatment paradigm. Eur J Pharmacol 184:43-53
63. Casey DE (1993): Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112:555-559
64. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG (1994): Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacology 14:119-125
65. Chai B, Meltzer HY (1992): The effect of chronic clozapine on basal dopamine release and apomorphine-induced dopamine release in the striatum and nucleus accumbens as measured by in vivo brain microdialysis. Neurosci Lett 140:47-50
66. Chen J, Paredes W, Gardner EL (1991): Chronic treatment with clozapine selectively decreases basal dopamine release in nucleus accumbens but not in caudate-putamen as measured by in vivo brain microdialysis: Further evidence for depolarization block. Neurosci Lett 122:127-131
67. Chen J, Ruan D, Paredes W, Gardner EL (1992): Effects of acute and chronic clozapine on dopaminergic function in medial prefrontal cortex of awake, freely moving rats. Brain Res 571:235-241
68. Cheng YF, Lundbert T, Bondesson U, Lindstrom L, Gabriels-son J (1988): Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 34:445-449
69. Cheung SW, Tang SW, Remington G (1991): Simultaneous quantification of loxapine, amoxapine, and their 7-and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr 564:213-221
70. 2 dopamine receptor in rat and bovine caudate nucleus. Nature 343:266-269
71. Chiodo LA, Bunney BS (1983): Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Neuroscience 3:1,607-1,619
72. Chiodo LA, Bunney BS (1985): Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2,539-2,544
73. Chipkin RE, Latranyi MB (1987): Similarity of clozapine and SCH-23390 in reserpinized rats suggests a common mechanism of action. Eur J Pharmacol 136:371-375
74. Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Crismon ML, Saklad SR, Hirschowitz J, Wagner R (1990): Single vs multiple dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 7:347-351
75. Choc MG, Lehr RG, Hsuan F, Honigfeld G, Smith HT, Bori-son R, Volavka J (1987): Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 4:402-405
76. Chouinard G, Annable L (1984): An early phase II clinical trial of BW 234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology 84:282-284
77. Clark D, White FJ (1987): Di dopamine receptor the search for a function. A critical evaluation of the Di/D2 dopamine receptor classification and its functional implications. Synapse 1:347-388
78. 2 receptors: Implications for drug mechanisms of action. Life Sci 39:2,571-2,580
79. Colon EJ (1972): Quantitative cytoarchitectonics of the human cerebral cortex in schizophrenic dementia. Acta Neu-ropathol (Berl) 20:1-10
80. Compton DR, Johnson KM (1989): Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accum-bens. J Pharmacol Exp Therap 248:521-530
81. Coupet J, Rauh CE (1979): 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of lox-apine and its hydroxylated metabolites. Eur J Pharmacol 55:215-218
82. Coward DM (1992): General pharmacology of clozapine. Br J Psychiatry 160 (suppl. 17):5-11
83. Coward DM, Imperato A, Urwyler S, White TG (1989): Biochemical and behavioural properties of clozapine. Psychopharmacology 99:56-512
84. Creese I, Burt DR, Snyder SH (1976): Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
85. Crismon ML, Ereshefsky L, Saklad SR (1988): A comparison of clozapine absorption in the postprandial versus fasting states. Pharm Res 5:S171
86. Criswell HE, Mueller RA, Breese GA (1989): Clozapine antagonism of Di and D2 dopamine receptor-mediated behaviors. Eur J Pharmacol 159:141-147
87. Cross A, Crow TJ, Owen F (1979): Gamma-aminobutyric acid in the brain in schizophrenia. Lancet 1:560-561
88. Crow TJ, Baker AJ, Gross MH, Joseph R, Longden A, Owen F, Riley GJ, Glover V, Killpack WS (1979): Monoamine mechanisms in chronic schizophrenia: Postmortem neurochemical findings. Br J Psychiatry 134:249-256
89. Czudek C, Reynolds GP (1990): (3H)-Nipecotic acid binding to GABA uptake sites in post-mortem human brain. J Neurochem 55:165-168
90. 2 receptors. Pharmacopsychiatry 26:53-58
91. 2 receptor: Two molecular forms generated by alternative splicing. EMBO J 8:4,025-4,034
92. Dall’Olio R, Roncada P, Vaccheri A, Gandolfi O, Montanaro N (1989): Synergistic blockade of some dopamine-mediated behaviors by (-)-sulpiride and SCH23390 in the rat. Psychopharmacology 98:342-346
93. Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S, Bigelow LB, Goldberg TE, Berman KF, Kleinman JE (1991): The effect of amphetamine on regional blood flow during cognitive activation in schizophrenia. J Neurosci 11:1,907-1,917
94. Davis KL, Kahn RS, Ko G, Davidson M (1991): Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148:1,474-1,486
95. De Keyser J, Claeys A, DeBacker JP, Ebinger G, Roels F, Vau-quelin G (1988): Autoradiographic localization of the Di and D2 dopamine receptors in human brain. Neurosci Lett 91:142-147
96. Deakin JFW, Slater P, Simpson MCD, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ (1989): Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52:1,781-1,786
97. Dearry A, Gingrich JA, Falardeau P, Fremeau RT Jr., Bates MD, Caron MG (1990): Molecular cloning and expression of the gene for a human Di dopamine receptor. Nature 347:72-76
98. DeLisi LE, Dauphinais ID, Gershon E (1988): Perinatal complications and reduced size of brain limbic structures in familial schizophrenia. Schizophr Bull 14:185-191
99. Della Vedova F, Fumagalli F, Sacchetti G, Racagni G, Brunello N (1992): Age-related variations in relative abundance of alternative spliced D2 receptor mRNAs in brain areas of two rat strains. Mol Brain Res 12:357-359
100. Deutch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989): A glutamatergic hypothesis of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neu-ropharmacol 12:1-13
101. Dohlman HG, Thorner J, Caron MG, Lefkowitz RJ (1991): Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 60:653-688
102. Domino E, Luby ED (1973): Abnormal mental states induced by phencyclidine as a model of schizophrenia. In Cole JO, Freedman AM, Friedhoff AJ (eds), Psychopathology and psychopharmacology. Johns Flopkins University Press, Baltimore, MD, pp 37-50
103. Drew KL, O'Connor WT, Kehr J, Ungersted U (1990): Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia. Eur J Pharmacol 187:385-397
104. Eichenberger E (1984): Pharmacology of fluperlapine compared with clozapine. Drug Res 34:110-113
105. Eidne KA, Taylor PL, Zabavnik J, Saunders PTK, Inglis JD (1994): D2 receptor, a missing exon. Nature 342:865
106. Ellenbroek BA, Artz MT, Cools AR (1991): The involvement of dopamine Di and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 196:103-108
107. Ereshefsky L, Watanabe MD, Tran-Jjohnson TK (1989): Clozapine: An atypical antipsychotic agent. Clin Pharmacol 8:691-709
108. Falkai P, Bogerts B (1986): Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci 236: 154-161
109. Falkai P, Bogerts B, Rozumek M (1988): Limbic pathology in schizophrenia: The entorhinal region. A morphometric study. Biol Psychiatry 24:515-521
110. Farde L, Nordstrom AL (1992): PET analysis indicates atypical dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 160 (suppl. 17): 30-33
111. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544
112. Farde L, Wiesel F-A, Stone-Elander S, Halldin C, Nordstrom AL, Hall H, Sedvall G (1990): D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 47:213-219
113. Farley I, Shannak K, Hornykiewicz D (1980): Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased dopamine receptor sensitivity. In Pepeu G, Kuhar M, Enna SJ (eds), Receptor for Neurotransmitters and Peptide Hormones. New York, Raven Press, pp 427-433
114. Fessier RG, Sturgeon RD, Meltzer HY (1979): Phencyclidine-induced ipsilateral rotation in rats with unilateral 6-hy-droxydopamine-induced lesions of the substantia nigra. Life Sci 24:1,281-1,288
115. Ford APDW, Marsden CA (1986): Influence of anaesthetics on rat striatal dopamine metabolism in vivo. Brain Res 379:162-166
116. Frangos E, Athanassenas G (1982): Differences in lateral brain ventricular size among various types of chronic schizophrenics: Evidence based on a CT scan. Acta Psychiatr Scand 66:459-463
117. Fremeau RT, Duncan GE, Fornaretto MG, Dearry AE, Gingrich JA, Breese GR, Caron MG (1991): Localization of Di dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci USA 88:3,772-3,776
118. 10 dopamine neurons. Neurosci Lett 119:159-162
119. Frey JM, Ticku MK, Huffman RD (1987): GABAergic supersensitivity within the pars reticulata of the rat substantia nigra following chronic haloperidol administration. Brain Res 425:73-84
120. Friedman E, Gianutsos G, Kuster J (1983): Chronic fluphena-zine and clozapine elicit opposite changes in brain muscarinic receptor binding: Implications for understanding tardive dyskinesia. J Pharmacol Exp Ther 226:7-12
121. Fuxe K, Hdkfelt T, Jonsson G, Lofstrom A (1974): Aminergic mechanism in neuroendocrine control. In Knowles F, Vollrath L (eds), Neurosecretion. The Final Neuroendocrine Pathway. Berlin, Springer-Verlag, pp 269-275
122. Farde L, Nordstrom AL (1992): PET analysis indicates atypical dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 160 (suppl. 17): 30-33
123. Gale K (1980): Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283:569-570
124. Gandelman KY, Harmon S, Todd RD, O'Malley KLJ (1991): Analysis of the structure and expression of the human dopamine D4A receptor gene. J Neurochem 56:1,024-1,029
125. Gardner EL, Walker LS, Paredes W (1993): Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: A brain stimulation study in the rat. Psychopharmacology 110:119-124
126. Gariano RF, Groves PM (1989): A mechanism for the involvement of colocalized neuropeptides in the action of antipsychotic drugs. Biol Psychiatry 26:303-314
127. Garver DL, Bissette G, Yao JK, Nemeroff CB (1991): CSF neurotensin concentrations in psychosis: relationship to symptoms and drug response. Am J Psychiatry 148: 485-488
128. Gattaz WF, Gasser T, Beckmann H (1985): Multidimensional analysis of the concentration of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry 20:360-366
129. Gattaz WF, Gattaz D, Beckmann H (1982): Glutamate in schizophrenics and healthy controls. Archives Psichiatrie Nervenkrankheiten 231:221-225
130. Gauch R, Michaelis W (1991): The metabolism of 8-chloro-ll-(4-methyl-l-piperazinyl)-5H-dibenzo[b, e]diazepine (clozapine) in mice, dogs, and human subjects. II Far-maco 26:667-681
131. Gelders YG (1989): Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry (suppl) 155:33-36
132. Gerfen CR, Engber TM, Susel Z, Chase TN, Mahan LC, Monsma FJ Jr, Sibley DR (1990): Di and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1,429-1,432
133. Gerlach J (1977): The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry 143:781-784
134. Gerlach J (1991): New antipsychotics: Classification, efficacy, and adverse effects. Schizophr Bull 17:289-309
135. Gerner R, Hare T (1981): CSF GABA in normal subjects and patients with depression, schizophrenia, mania and anorexia nervosa. Am J Psychiatry 138:1,098-1,101
136. Gershanik O, Heikkila RE, Duvoisin RC (1983): Behavioral correlations of dopamine receptor activation. Neurology 33:1,489-1,492
137. Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R (1994): BMY14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10:37-40
138. 2, opiate and benzodiazepine receptors in the rat brain after long-term treatment. J Neural Transm (Gen Sect) 83:189-203
139. Giros B, Martres MP, Sokoloff P, Schwartz JC (1990): Clonage du gene du recepteur dopaminergique D3 humain et identification de son chromosome. CR Acad Sci 311: 501-508
140. Giros B, Sokoloff P, Martres MP, Riou JF, Emorine LJ, Schwartz JC (1989): Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 342:923-926
141. Gold B, Bowers MB, Roth R, Sweeney P (1980): GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry 137:362-364
142. Golden CJ, Graber B, Coffman J, Berg RA, Newlin DB, Bloch S (1981): Structural brain deficits in schizophrenia: Identification by computed tomographic scan density measurements. Arch Gen Psychiatry 38:1014-1017
143. Gale K (1980): Chronic blockade of dopamine receptors by antischizophrenic drugs enhances GABA binding in substantia nigra. Nature 283:569-570
144. 4A receptor gene. J Neurochem 56:1024-1029
145. Gardner EL, Walker LS, Paredes W (1993): Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: A brain stimulation study in the rat. Psychopharmacology 110:119-124
146. Gariano RF, Groves PM (1989): A mechanism for the involvement of colocalized neuropeptides in the action of antipsychotic drugs. Biol Psychiatry 26:303-314
147. Garver DL, Bissette G, Yao JK, Nemeroff CB (1991): CSF neurotensin concentrations in psychosis: relationship to symptoms and drug response. Am J Psychiatry 148: 485-488
148. Gattaz WF, Gasser T, Beckmann H (1985): Multidimensional analysis of the concentration of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry 20:360-366
149. Gattaz WF, Gattaz D, Beckmann H (1982): Glutamate in schizophrenics and healthy controls. Archives Psichiatrie Nervenkrankheiten 231:221-225
150. Gauch R, Michaelis W (1991): The metabolism of 8-chloro-ll-(4-methyl-l-piperazinyl)-5H-dibenzo[b, e]diazepine (clozapine) in mice, dogs, and human subjects. II Far-maco 26:667-681
151. Gelders YG (1989): Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry (suppl) 155:33-36
152. Gerfen CR, Engber TM, Susel Z, Chase TN, Mahan LC, Monsma FJ Jr., Sibley DR (1990): Di and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250:1429-1432
153. Gerlach J (1977): The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry 143:781-784
154. Gerlach J (1991): New antipsychotics: Classification, efficacy, and adverse effects. Schizophr Bull 17:289-309
155. Gerner R, Hare T (1981): CSF GABA in normal subjects and patients with depression, schizophrenia, mania and anorexia nervosa. Am J Psychiatry 138:1098-1101
156. Gershanik O, Heikkila RE, Duvoisin RC (1983): Behavioral correlations of dopamine receptor activation. Neurology 33:1489-1492
157. Gewirtz GR, Gorman JM, Volavka J, Macaluso J, Gribkoff G, Taylor DP, Borison R (1994): BMY14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10:37-40
158. 2, opiate and benzodiazepine receptors in the rat brain after long-term treatment. J Neural Transm (Gen Sect) 83:189-203
159. Giros B, Martres MP, Sokoloff P, Schwartz JC (1990): Clonage du gene du recepteur dopaminergique D3 humain et identification de son chromosome. CR Acad Sci 311: 501-508
160. Giros B, Sokoloff P, Martres MP, Riou JF, Emorine LJ, Schwartz JC (1989): Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature 342:923-926
161. Gold B, Bowers MB, Roth R, Sweeney P (1980): GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry 137:362-364
162. Golden CJ, Graber B, Coffman J, Berg RA, Newlin DB, Bloch S (1981): Structural brain deficits in schizophrenia: Identification by computed tomographic scan density measurements. Arch Gen Psychiatry 38:1014-1017
163. Goldstein SR, Matsumoto RR, Thompson TL, Patrick RL, Bowen WD, Walker JM (1989): Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 4:254-258
164. Govoni S, Hong JS, Yang H-YT, Costa E (1980): Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J Pharmacol Exp Ther 215:413-417
165. Grace AA, Bunney BS (1986): Induction of depolarization block in midbrain dopamine neurons by repeated ad-ministration of haloperidol: Analysis using in vivo intracellular recording. J Pharmacol Exp Ther 238:1092-1100
166. Grace AA (1991): Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24
167. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fisher JB, Burke-Howie KJ, Bunzow JR, Server AC, Civelli O (1989): Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86:9762-9766
168. Grandy DK, Zhang Y, Bouvier C, Zhou QY, Johnson RA, Allen L, Buck K, Bunzow JR, Salon J, Civelli O (1991): Multiple human D5 dopamine receptor genes: A functional receptor and two pseudogenes. Proc Natl Acad Sci US A 88:9175-9179
169. Griffiths EC, McDermott JR, Smith AI (1984): A comparative study of neurotensin inactivation by brain peptidases from different vertebrate species. Comp Biochem Physiol 77C:363-366
170. Gruen RJ, Roth RH, Bunney BS, Moghadam B (1990): Increase in striatal dopamine release following local perfusion of the NMDA receptor antagonist 2-amino-5-phosphono-pentanoic acid. Soc Neurosci Abstr 16:679
171. Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori T, Meltzer HY (1987): Differential-effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. J Neural Transm 68:227-240
172. Gudelsky GA, Nash JF, Berry SA, Meltzer HY (1989): Basic biology of clozapine: Electrophysiological and neuroendocrinological studies. Psychopharmacology 99:S13-S17
173. Gunne L-M, Haggstrom J-E, Sjoquist B (1984): Association with persistent neuroleptic-induced dyskinesia of re-gional changes in brain GABA synthesis. Nature 309: 347-349
174. Gunne LM, Haggstrom J-E (1983): Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced dyskinesia. Psychopharmacology 81:191-194
175. Hall H, Farde L, Sedvall G (1988): Human dopamine receptor subtypes: In vitro binding analysis using 3H-SCH23390 and 3H-raclopride. J Neural Transm 73:7-21
176. Hanada S, Mita T, Nishinok N, Tanaka C (1987): 3H-muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 40:259-266
177. Hare T, Word J, Bala-Manyam N, Ballenger J, Post R, Gerner R (1980): Selection of control populations for clinical cerebrospinal fluid GABA investigations based on comparison with normal volunteers. Brain Res Bull 5:721-724
178. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhiiber H (1989): Dose-related plasma levels of clozapine influence of smoking behavior, sex and age. Psychopharmacology 99 (suppl.): 538-540
179. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A (1990): Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 147:1471-1475
180. Harrison PJ, McLaughlin D, Kerwin RW (1991): Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 337:450-452
181. Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, Nishino N, Tanaka C (1993): Differential changes in serotonin 5-HTla and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychophar-macology 112:535-539
182. Hashimoto T, Nishino N, Nakai H, Tanaka C (1991): Increase in 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with schizophrenia. Life Sci 48:355-363
183. Heckers S, Heinsen H, Geiger B, Beckmann H (1991): Hippocampal neuron number in schizophrenia. Arch Gen Psychiatry 48:1002-1008
184. Heckers S, Heinsen H, Heinsen Y, Beckmann H (1990): Limbic structures and lateral ventricle in schizophrenia. Arch Gen Psychiatry 47:1016-1022
185. Heritch AJ (1990): Evidence for reduced and dysregulated turnover of dopamine in schizophrenia. Schizophr Bull 16:605-615
186. Hetey L, Drescher K (1986): Influence of antipsychotic are presynaptic receptors modulating the release of dopamine in synaptosomes of the nucleus accumbens of rats. Neuropharmacology 25:1103-1109
187. Hicks PB (1990): The effect of serotonergic agents on halo-peridol-induced catalepsy. Life Sci 47:1609-1615
188. Hiemke C, Weigmann H, Hårtter S, Dahmen N, Wetzel H, Muller H (1994): Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281
189. Hietala J, Koulu M, Kuoppamåki M, Lappalainen J, Syvålahti E (1992): Chronic clozapine treatment downregulates serotonin 5-HTlc receptors in rat brain. Prog Neuropsy-chopharmacol & Biol Psychiatry 16:727-732
190. Hoffman BJ, Mezey E (1989): Distribution of serotonin 5-HTlc receptor mRNA in adult rat brain. FEBS Lett 247:453-462
191. Imperato A, Angelucci L (1989): The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and the prefrontal cortex of freely moving rats. Psychopharmacol Bull 25:383-389
192. Imperato A, Scrocco MG, Bacchi S, Angelucci L (1990): NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 187:555-556
193. Invernizzi R, Morali F, Pozzi L, Samanin R (1990): Effects of acute and chronic clozapine on dopamine release and metabolism in the striatum of conscious rats. Br J Pharmacol 100:774-778
194. Iversen LL (1993): The D4 and schizophrenia. Nature 365:393
195. Jackson DM, Mohell N, Bengtsson A, Malmberg A (1993): What are atypical neuroleptics and how do they work? In Brunello N, Mendlewicz J, Racagni G (eds), New generation of antipsychotic drugs: Novel mechanisms of action. Int Acad Biomed Drug Res, vol 4, Basel, Karger, pp 27-38
196. Jakob H, Beckmann H (1986): Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 65:303-326
197. Jann MW, Grimsley SR, Gray EC, Chang WH (1993): Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinetics 24:161-176
198. Javitt DC (1987): Negative symptomatology and the PCP (phencyclidine) model of schizophrenia. Hill-side. J Clin Psychiatry 9:12-35
199. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
200. Jeste DV, Lohr JB (1989): Hippocampal pathological findings in schizophrenia: a morphometric study. Arch Gen Psychiatry 46:1019-1024
201. Johnstone EC, Crow TJ, Ferrier IN, Firth CD, Owens DGC, Bourne RC, Gamble SJ (1983): Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 13:513-527
202. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L (1976): Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 2:924-926
203. Jones RSG (1993): Entorhinal-hippocampal connections: A speculative view of their function. Trends Neurosci 16:58-64
204. Joseph MH, Baker HF, Crow TJ, Riley GJ, Rigsby D (1979): Brain tryptophan metabolism in schizophrenia: A postmortem study of metabolites on the serotonin and kynurenine pathways in schizophrenia and control subjects. Psychopharmacology 62:279-285
205. Joyce JN (1993): The dopamine hypothesis of schizophrenia: Limbic interactions with serotonin and norepinephrine. Psychopharmacology 112:S16-S34
206. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993): Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336
207. Kahn RS, Davidson M (1993): Serotonin, dopamine and their interactions in schizophrenia. Psychopharmacology 112: S1-S4
208. Kane J, Honigfeld G, Singer J, Meltzer HY (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
209. Kane J, Honigfeld G, Singer J, Meltzer H (1989): Clozapine for treatment-resistant schizophrenic: Results of a US multicenter trial. Psychopharmacology 99.S60-S63
210. Kane JM (1993): Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. Drugs 46: 585-593
211. Kanterman RY, Mahan LC, Briley EM, Monsma FJ Jr, Sibley DR, Axelrod J, Felder CC (1991): Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol Pharmacol 39:364-369
212. Kelland MD, Freeman AS, Chiodo LA (1989): Chloral hydrate anesthesia alters the responsiveness of identified midbrain dopamine agonist administration. Synapse 3:30-37
213. Kelland MD, Freeman AS, Chiodo LA (1990): Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopaminergic neurons. J Pharmacol Exp Ther 253:803-811
214. Kelsoe JR, Cadet JL, Pickar D, Weinberger DR (1988): Quantitative neuroanatomy in schizophrenia: a controlled magnetic resonance imaging study. Arch Gen Psychiatry 45:533-541
215. Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds GP (1988): Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1:583-584
216. Kilts CD, Anderson CM, Bissette G, Ely TD, Nemeroff CB (1988): Differential effects of antipsychotic drugs on the neurotensin content of discrete brain nuclei. Biochem Pharmacol 37:1547-1554
217. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B (1980): Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382
218. Kitabgi P (1989): Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways. Neurochem Int 14:111-119
219. Klawans HL (1973): The pharmacology of tardive dyskinesias. Am J Psychiatry 130:82-86
220. Kohler C, Hall H, Magnusson O, Lewander T, Gustafsson K (1990): Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr Scand 82 (suppl. 358): 27-36
221. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991): Effects of the 1-amino-adamantanes at the MK-801-binding site of NMDA-receptor-gated ion channel-a human postmortem brain study. Eur J Pharmacol (Mol Pharmacol Sect) 206:297-300
222. Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P (1989): Memantine displaces (3H)MK-801 at therapeutic concentrations in post-mortem human frontal cortex. Eur J Pharmacol 166:589-590
223. Kornhuber J, Weller M (1993): Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. J Neural Transm 92:57-65
224. Korpi ER, Kaufman CA, Marneal K-M, Weinberger DR (1987): Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res 20:337-345
225. Korpi ER, Kleinman JE, Goodman SI, Phillips I, DeLisi LE, Linnoila M, Wyatt RJ (1986): Serotonin and 5-hydroxy-indolacetic acid in the brain of suicide victims: Comparison in chronic schizophrenic patients with suicide as the cause of death. Arch Gen Psychiatry 43:594-600
226. Kostowski W, Gumulka W, Czlonkowski A (1972): Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenyl-alanine. Brain Res 48:443-446
227. Kovelman JA, Scheibel AB (1984): A neurohistological correlate of schizophrenia. Biol Psychiatry 19:1601-1621
228. Krebs MO, Desce JM, Kernel ML, Gauchy C, Godeheu G, Cheramy A, Glowinski J (1991): Glutamatergic control of dopamine release in the rat striatum: Evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J Neurochem 56:81-85
229. Krupp P, Barnes P (1992): Clozapine-associated agranulocytosis: Risk and aetiology. Br J Psychiatr 160 (suppl. 17): 38-40
230. Kuoppamåki M, Pålvimåki EP, Syvålahti E, Hietala J (1994): 5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine. Eur] Pharmacol 255:91-97
231. Kuoppamåki M, Seppala T, Syvålahti E, Hietala J (1993a): Chronic clozapine treatment decreases 5-hydroxytryp-tamine lc receptor density in the rat choroid plexus: Comparison with haloperidol. J Pharmacol Exp Ther 264: 1262-1267
232. Kuoppamåki M, Syvålahti E, Hietala J (1993b): Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol (Mol Pharmacol Sect) 245: 179-182
233. Lahti RA, Evans DL, Stratman NC, Figur LM (1993): Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: Possible therapeutic implications. Eur J Pharmacol 236:483-486
234. Lamberts SWJ, van Koetsveld PM, Hofland LJ (1990): The effect of clozapine on prolactin secretion at the level of the lactotroph. Life Sci 46:1013-1019
235. Lane RF, Blaha CD (1986): Electrochemistry in vivo: Application to CNS pharmacology. Ann NY Acad Sci 473:50-69
236. Lane RF, Blaha CD, Rivet JM (1988): Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: Involvement of alpha 1-norad-renergic receptor demonstrated by in vivo voltammetry. Brain Res 460:398-401
237. Le Moine C, Normand E, Bloch B (1991): Phenotypical characterization of the rat striatal neurons expressing the Di dopamine receptor gene. Proc Natl Acad Sci USA 88: 4205-4209
238. Le Moine C, Tison F, Bloch B (1990): D2 dopamine receptor gene-expression by cholinergic neurons in the rat striatum. Neurosci Lett 117:248-252
239. Lee T, Seeman P, Tourtellotte WW, Farley IJ, Hornykiewicz O (1978): Binding of 3H-neuroleptics and 3H-apomor-phine in schizophrenic brains. Nature 274:897-900
240. Leeman SE, Carraway RE (1982): Neurotensin: Discovery, isolation, characterization, synthesis, and possible physiological roles. Ann NY Acad Sci USA 400:1-16
241. Levant B, Bissette G, Davis D, Heffner TG, Nemeroff CB (1991): Effects of Cl-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations. Synapse 9:225-230
242. Levant B, Nemeroff CB (1988): The psychobiology of neurotensin. Curr Top Neuroendocrinol 8:231-262
243. Levant B, Nemeroff CB (1990): Sigma receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. J Pharmacol Exp Ther 254:330-335
244. Levin S, Yurgelin-Todd D, Craft S (1989): Contributions of clinical neuropsychology to the study of schizophrenia. J Abnorm Psychol 98:341-356
245. Lewander T, Westerbergh SE, Morrison D (1990): Clinical profile of remoxipride: A combined analysis of a comparative double-blind multicenter trial programme. Acta Psychiatr Scand 82 (suppl. 358):92-98
246. 2 receptors in rat striata and mesolimbic tissues using [125]-2'-iodospiperone. Psychopharmacology 110: 27-36
247. Leysen JE, Janssen P, Gommeren W, Wynants J, Pauwels PJ, Janssen PAJ (1992): In vitro and in vivo binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41:494-508
248. Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993b): Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112:S40-S54
249. Lichstein D, Dobkin J, Ebstein R, Biederman J, Rimon R, Bel-maker R (1978): Gammaaminobutyric acid (GABA) in the CSF of schizophrenic patients before and after neuroleptic treatment. Br J Psychiatry 132:145-148
250. 4 (DRD4) gene. Hum Mol Genet 2:767-773
251. Lidsky TI, Yablonsky-Alter E, ZuckL, Banerjee SP (1993): An-tiglutamatergic effects of clozapine. Neurosci Lett 163: 155-158
252. Lieberman J, Johns C, Pollack S (1991): Effects of clozapine on amine metabolites in cerebrospinal fluid of schizophrenic patients. In Tamminga CA, Schultz SC (eds), Schizophrenia Research. New York, Raven Press, pp 341-349
253. Lieberman JA, Kane JM, Johns CA (1989): Clozapine: Guidelines for clinical management. J Clin Psychiatry 50:329-338
254. Lindstrom LH (1988): The effect of long-term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 77:524-529
255. Lindstrom LH, Widerlov E, Bissette G, Nemeroff CB (1988): Reduced CSF neurotensin concentration in drug-free schizophrenic patients. Schizophr Res 1:55-59
256. Lipska BK, Jaskiw GE, Chrapusta S, Karoum F, Weinberger DR (1992): Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res 585:1-6
257. Lovenberg TW, Erlander MG, Baron MG, Racke M, Slone AL, Siegel BW, Craft CM, Burns JE, Danielson PE, Sutcliffe JG (1993): Molecular cloning and functional expression of 5-HTlE-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci USA 90:2184-2188
258. Mack KJ, Todd RD, O'Malley KL (1991): The mouse dopamine D2A receptor gene: Sequence homology with the rat and human genes and expression of alternative transcripts. J Neurochem 57:795-801
259. MacKay AP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH (1982): Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39:991-997
260. Maidment NT, Marsden C (1987): Acute administration of clozapine, thioridazine and metoclopramide increases extracellular DOPAC and decreases extracellular 5-HIAA, measured in the nucleus accumbens and striatum of the rat using in vivo voltammetry. Neuropharmacology 26: 187-193
261. Maj J, Mogilnicka E, Przewlocka B (1975): Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy. Pharmacol Biochem Behav 3:25-27
262. Manberg PJ, Nemeroff CB, Bissette G, Prange AJ Jr, Gerner RH (1983): Cerebrospinal fluid levels of neurotensin-like immunoreactivity in normal controls and in patients with affective disorder, anorexia nervosa and premenstrual syndrome. Soc Neurosci Abstr 9:1054
263. 2 receptor binding in the rat brain striatum and pituitary an in situ hybridization receptor. J Neurosci 10:2587-2600
264. 4 dopamine receptor mRNAs in the rat brain: An in situ hybridization study. Soc Neurosci Abstr 17:599
265. Mao CC, Cheney DL, Marco E, Revuelta A, Costa E (1977): Turnover times of gamma-aminobutyric acid and acetylcholine in nucleus caudatus, nucleus accumbens, globus pallidus and substantia nigra: Effects of repeated administration of haloperidol. Brain Res 132:375-379
266. Marco E, Mao CC, Cheney DL, Revuelta A, Costa E (1976): The effects of antipsychotics on the turnover rate of GABA and acetylcholine in rat brain nuclei. Nature 264:363-365
267. Markstein R (1986): Pharmacological characterization of dopamine receptors using functional criteria. In Winlow W, Markstein R (eds), Neurobiology of Dopamine Systems. Manchester, University Press, pp 40-52
268. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976): The effects of morphine-and nalorphine-like drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532
269. Mason SL, Reynolds GP (1992): Clozapine has sub-micromolar affinity for 5-HTla receptors in human brain tissue. Eur J Pharmacol 221:397-398
270. 2 and serotonin receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265:498-508
271. Matsubara S, Meltzer HY (1989): Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci 45:1397-1406
272. McPherson SE, Loo P, Braunwalder A, Wood PL (1987): Enhancement of the in vivo binding of 3H-flunitrazepam by the atypical neuroleptic, clozapine. Neuropharmacology 26:265-269
273. 2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA 86:7625-7628
274. 5 dopamine receptor mRNAs in the human brain. Soc Neurosci Abstr 17:599
275. 5 dopamine receptor mRNA in rat brain. Neurosci Lett 145: 209-212
276. Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27
277. Meltzer HY (1991a): The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287
278. Meltzer HY (1991b): Studies of ondansetron in schizophrenia. In Racagni G, Brunello N, Fukuda T (eds), Biological Psychiatry. Excerpta Medica vol 2, pp 891-893
279. Meltzer HY, Chai BL, Thompson PA, Yamamoto BK (1994): Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol, or thioridazine. J Pharmacol Exp Ther 268:1452-1461
280. Meltzer HY, Daniels S, Fang VS (1975): Clozapine increases rat serum prolactin levels. Life Sci 17:339-342
281. Meltzer HY, Gudelsky GA (1992): Dopaminergic and serotonergic effects of clozapine. Implication for a unique clinical profile. Arzneimittel-Forsch Drug Res 42:268-272
282. 2 and serotoninz pK values. J Pharmacol Ex-per Ther 251:238-246
283. Meltzer HY, Nash JF (1991): Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604
284. Meltzer LT, Christoffersen CL, Serpa KA, Pugsley TA, Razm-pour A, Heffner TG (1992): Lack of involvement of haloperidol-sensitive sigma binding sites in modulation of dopamine neuronal activity and induction of dystonias by antipsychotic drugs. Neuropharmacology 31: 961-967
285. Mengod G, Martinez-Mir MI, Vilaro' MT, Palacios JM (1989): Localization of the mRNA for the dopamine D2 receptor in the rat brain by in situ hybridization histochemistry. Proc Natl Acad Sci USA 86:8560-8564
286. Mengod G, Nguyen H, Le H, Waeber C, Lobbert H, Palacios JM (1990): The distribution and cellular localization of the serotonin lc receptor mRNA in the rodent brain examined by in situ hybridization histochemistry. Comparison with receptor binding distribution. Neuroscience 35:577-591
287. Mengod G, Vilaro MT, Niznik HB, Sunahara RK, Seeman P, O'Dowd BF, Palacios JM (1991): Visualization of a dopamine Di receptor mRNA in human and rat brain. Brain Res 10:185-191
288. Merchant KM, Miller MA, Ashleigh EA, Dorsa DM (1991): Haloperidol rapidly increases the number of neurotensin mRNA-expressing neurons in neostriatum of the rat brain. Brain Res 540:311-314
289. Merchant KM, Dorsa DM (1993): Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci USA 90:3447-3451
290. Meyerhof W, Obermuller F, Fehr S, Richter D (1993): A novel rat serotonin receptor: Primary structure, pharmacology and expression pattern in distinct brain regions. DNA Cell Biol 12:401-409
291. 2) receptor. Biochem Biophys Res Commun 166:109-112
292. Miller RJ, Hiley CR (1974): Antimuscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248: 596-597
293. Miller RJ, Hiley CR (1976): Anti-dopaminergic and antimuscarinic effects of dibenzodiazepines: Relationship to drug-induced parkinsonism. Naunyn-Schmiedeberg's Arch Pharmacol 292:289-293
294. 2 in chronic schizophrenics. Biol Psychiatry 21:1407-1414
295. Mitchell PR, Doggett NS (1980): Modulation of striatal [3H]glu-tamic acid release by dopaminergic drugs. Life Sci 26: 2073-2081
296. Moghaddam B, Bunney BS (1990): Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: An in vivo microdialysis study. J Neurochem 54:1755-1760
297. Molineaux SA, Jessell TM, Axel R, Julius D (1989): 5-HTlc receptor is a prominent serotonin receptor subtype in the central nervous system. Proc Natl Acad Sci USA 86: 6793-6797
298. Monnet FP, Debonnel G, de Montigny C (1992): In vivo elec-trophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther 261:123-130
299. Monsma FJ Jr, Mahan LC, McVittie LD, Gerfen CR, Sibley DR (1990): Molecular cloning and expression of a Di dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci USA 87:6723-6727
300. 2 dopamine receptors produced by alternative RNA splicing. Nature 342:926-929
301. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (1995): Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43:320-327
302. 2 dopamine receptor isoforms. FEBS Lett 278:239-243
303. 2 receptor-mediated function: Behavioural indices. Eur J Pharmacol 186:79-86
304. 2-dopaminergic receptor detected by in situ hybridization histochemistry in rat brain. FEBS Lett 255:335-339
305. Nash JF, Meltzer HY, Gudelsky GA (1988): Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmacol 151:463-468
306. Nasrallah HA, Jacoby CG, McCalley-Whitters M, Kuperman S (1982): Cerebral ventricular enlargement in subtypes of chronic schizophrenia. Arch Gen Psychiatry 39:774-777
307. Nemeroff CB, Youngblood W, Manberg PJ, Prange AJ Jr, Kizer JS (1983): Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science 221:972-975
308. Neve K, Henningsen RA, Bunzow JR, Civelli O (1989): Functional characterization of a rat dopamine D2 receptor cDNA expressed in a mammalian cell line. Mol Pharmacol 36:446-451
309. Nishikawa T, Takashima M, Toru M (1983): Increased (3H)-kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 40:245-250
310. Nordstrom AL, Farde L, Halldin C (1993): High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 110:365-367
311. Nyback H, Wiesel FA, Berggren BM, Hindmarsh T (1982): Computed tomography of the brain in patients with acute psychosis and in health volunteers. Acta Psychiatr Scand 65:403-414
312. Nylander I, Terenius L (1986): Chronic haloperidol and clozapine differentially affect dynorphin peptides and substance P in basal ganglia of the rat. Brain Res 380:34-41
313. O'Dell S, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF (1990): Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6:146-153
314. O'Dowd BF, Nguyen T, Tirpak A, Jarvie KR, Israel Y, See-man P, Niznik HB (1990): Cloning of two additional catecholamine receptors from rat brain. FEBS Lett 262:8-12
315. 2A receptor gene: Identification of alternative transcripts and a variant donor splice site. Biochemistry 29:1367-1371
316. Owen F, Cross AJ, Crow TJ, Lofthouse R, Poulter M (1981): Neurotransmitter receptors in brain in schizophrenia. Acta Psychiatr Scand 63:20-27
317. Owen F, Crow TJ, Poulter M, Cross AJ, Longden A, Riley GJ (1978): Increased dopamine-receptor sensitivity in schizophrenia. Lancet 2:223-225
318. Owens DG, Johnstone EC, Crow TJ, Frith CD, Jagoe JR, Kreel L (1985): Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychol Med 15:27-41
319. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991): Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231-235
320. Perry TL (1982): Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurose Lett 28:81-85
321. Perry TL, Buchanan J, Kish S, Hausen S (1979): Gamma-aminobutyric acid deficiency in brain of schizophrenic patients. Lancet 1:237-239
322. Plassat JL, Amlaiky N, Hen R (1993): Molecular cloning of a mammalian serotonin receptor that activates adenylyl cyclase. Mol Pharmacol 44:229-236
323. Potkin SG, Bera R, Gulasekram B, Jin Y, Costa J, Gerber B, Richmond G, Ploszaj D, Carreon D, Cooper T, Stang-gan K (1993): Plasma clozapine concentrations associated with clinical efficacy. Biol Psychiatry 33 (suppl.):129A
324. Racagni G, Cheney DL, Trabucchi M, Costa E (1976): In vivo actions of clozapine and haloperidol on the turnover rate of acetylcholine in rat striatum. J Pharmacol Exp Ther 196:323-332
325. Ramirez OA, Wang RY (1986): Locus coeruleus norepinephrine-containing neurons: Effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine. Brain Res 362:165-170
326. Rao DD, McKelvy J, Kebabian J, MacKenzie RG (1990): Two forms of the rat D2 dopamine receptor as revealed by polymerase chain reaction. FEBS Lett 263:18-22
327. Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1990): Interaction of phencyclidine receptor agonist MK-801 with dopaminergic system: Regional studies in the rat. J Neurochem 57:1157-1162
328. Rasmussen K, Aghajanian GK (1988): Potency of antipsy-chotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology 1:101-107
329. Reynolds GP, Czudek C, Andrews HA (1990): Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry 27:1038-1044
330. Reynolds GP, Rossor M, Iversen LL (1983): Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm 18 (suppl.):273-277
331. Reynolds GP, Stroud D (1993): Hippocampal benzodiazepine receptors in schizophrenia. J Neural Transm (Gen Sect) 93:151-155
332. Richelson E (1984): Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45:331-336
333. Riederer P, Lange KW, Kornhuber J, Danielczyk W (1991): Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet 338:1022-1023
334. Roberts E (1972): Prospects for research on schizophrenia: An hypothesis suggesting that there is a defect in the GABA system in schizophrenia. Neurosci Res Program Bull 10:468-482
335. Roberts PJ, Anderson SD (1979): Stimulatory effect of L-glu-tamate and related amino acids on 3H-dopamine release from rat striatum: An in vitro model for glutamate actions. J Neurochem 32:1539-1545
336. Roberts PJ, McBean GJ, Sharif NA, Thomas EM (1982): Striatal glutamatergic function: Modifications following specific lesions. Brain Res 235:83-91
337. Robertson GS, Robertson HA (1986): Synergistic effects of Di and D2 dopamine agonists on turning behaviour in rats. Brain Res 384:387-390
338. Rosengarten H, Schweitzer JW, Friedhoff AJ (1983): Induction of oral dyskinesias in naive rats by Di stimulation. Life Sci 33:2479-2482
339. Rosenthaier J, Nimmerfall F, Munzer H (1977): Nonequilibrium method for the radioimmunoassay of cloza pine in the presence of metabolites. Eur J Biochem 80:603-609
340. Roth B, Ciaranello RD, Meltzer HY (1992): Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260:1361-1365
341. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer FIY, Sibley DR (1994): Binding of typical and atypical antipsychotic agents to 5-hydroxytrypt-amine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
342. Roth RH, Wolf ME, Deutch AY (1987): Neurochemistry of midbrain dopamine systems. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York, Raven Press, pp 81-95
343. Rothman S (1988): Non-competitive N-methyl-D-aspartate antagonists affect multiple ionic currents. J Pharmacol Exp Ther 246:137-142
344. Rowlands GJ, Roberts PJ (1980): Activation of dopamine receptors inhibits calcium-dependent glutamate release cortico-striatal terminals in vitro. Eur J Pharmacol 62:239-242
345. Ruat M, Traiffort E, Arrang JM, Tardivel-Iacombe J, Diaz J, Leurs R, Schwartz JC (1993a): A novel rat serotonin (5-HT6) receptor-molecular cloning, localization, and stimulation of cAMP accumulation. Biochem Biophys Res Commun 193:268-276
346. Ruat M, Traiffort E, Leurs R, Tardivel-Iacombe J, Diaz J, Ar-rang JM, Schwartz JC (1993b): Molecular cloning, characterization and localization of a high affinity serotonin receptor (5-HT7) activating cAMP formation. Proc Natl Acad Sci 90:8547-8551
347. Rubin P, Holm S, Friberg L, Videbech P, Andersen HS, Bend-sen BB, Stromso N, Larsen JK, Lassen NA, Hemming-sen R (1991): Altered modulation of prefrontal and subcortical brain activity in novel diagnosed schizophrenia and schizophreniform disorder: A regional cerebral blood flow study. Arch Gen Psychiatry 48:987-995
348. Rubin P, Karle A, Moller-Madsen S, Hertel C, Povlsen UJ, Noring U, Hemmingsen R (1993): Computerized tomography in newly diagnosed schizophrenia and schizophreniform disorder. A controlled double blind study. Br J Psychiatry 163:604-612
349. Rubinstein JE, Hitzemann RJ, Ashby CR Jr, Wang RY (1989): Long-term treatment with antipsychotics does not alter the phosphoinositide response to muscarinic or D2 dopaminergic agonists in rat striatum. Brain Res 496: 385-388
350. Rupniak NMJ, Hall M, Mann S, Fleminger S, Kilpatrick G, Jenner P, Marsden D (1985): Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D2 receptor function in the rat. Biochem Pharmacol 34:2755-2763
351. Salin P, Mecugliano M, Cheselet MF (1990): Differential effects of chronic treatment with haloperidol and clozapine on the level of pre-pro-somatostatin mRNA in the striatum, nucleus accumbens, and frontal cortex of the rat. Cell Mol Neurobiol 10:127-143
352. 2 dopamine receptor blockade. J Pharmacol Exp Ther 253:1162-1170
353. Sanger DJ (1985): The effects of clozapine on shuttle-box avoidance responding in rats: Comparisons with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav 23: 231-236
354. Sayers AC, Amsler HA (1977): Clozapine. In Goldberg ME (ed), Pharmacological and Biochemical Properties of Drug Substances. Am Pharmaceut Assn Acad Pharmaceut Sci, vol 1, pp 1-31
355. Scheibel AB, Kovelman JA (1981): Disorientation of the hippocampal pyramidal cell and its processes in the schizophrenic patient. Biol Psychiatry 16:101-102
356. Schmidt WJ, Krahling H, Ruhland M (1991): Antagonism of AP-5-induced sniffing stereotypy links Umespirone to atypical antipsychotics. Life Sci 48:499-505
357. Schmutz J (1975): Neuroleptic piperazinyl-dibenzo-azepines Drug Res 25:712-720
358. Schmutz J, Eichenberger E (1992): In Pindra JS, Lednicer D (eds), Chronicles of Drug Discovery. New York, John Wiley and Sons, vol 1, pp 39-59
359. Schulsinger F, Parnas J, Petersen ET, Schulsinger H, Teas-dale TW, Mednick SA, Moller L, Silverton L (1984): Cerebral ventricular size in the offspring of schizophrenic mothers. A preliminary study. Arch Gen Psychiatry 41:602-606
360. Schulz SC, Roller MM, Kishore PR, Hamer RM, Gehl JJ, Friedel RO (1983): Ventricular enlargement in teenage patients with schizophrenia spectrum disorder. Am J Psychiatry 140:1592-1595
361. Schwarcz R, Creese I, Coyle JT, Snyder SH (1978): Dopamine receptors localized on cerebral cortical afferents to rat corpus striatum. Nature 271:766-768
362. Schwartz WJ, Krahling H, Ruhland M (1987): Antagonism of AP-5-and amphetamine-induced behaviour by timelo-tem as compared with clozapine and haloperidol. Life Sci 41:1909-1914
363. Scottish Schizophrenia Research Group, MacDonald HL, Best JJK (1989): The Scottish first episode schizophrenia study: Computed brain scan in patients and controls. Br J Psychiatry 154:492-498
364. Seabrook GR, Patel S, Marwood R, Emms F, Knowles MR, Freedman SB, McAllister G (1992): Stable expression of human D3 dopamine receptors in GH4C1 pituitary cells. FEBS Lett 312:123-126
365. Sedvall G (1992): The current status of PET scanning with respect to schizophrenia. Neuropsychopharmacology 7:41-54
366. Sedvall G (1993): Brain imaging and the treatment of mental disorders. In Mendlewicz J, Brunello N, Langer SZ, Racagni G (eds), New Pharmacological Approaches to the Therapy of Depressive Disorders. Int Acad Biomed Drug Res, vol. 5, Basel, Karger, pp 176-183
367. 4. Neuropsychopharmacology 7:261-284
368. 2 receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1:5-15
369. Seeman P, Guan HG, Van Tol HHM (1993): Dopamine D4 receptors elevated in schizophrenia. Nature 365:441-445
370. Seeman P, Lee T, Chau-Wong M, Wong K (1976): Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719
371. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci 86:10156-10160
372. Seeman P, Van Tol HHM (1994): Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270
373. Selbie LA, Hayes G, Shine J (1989): The major dopamine D2 receptor. Molecular analysis of human D2A-subtype. DNA 8:683-689
374. Sesack SR, Deutch AY, Roth RH, Bunney BS (1989): Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: An anterograde tracttracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol 290:213-242
375. Sesack SR, Pickel VM (1990): In the rat medial nucleus ac-cumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res 527:266-279
376. Shaikh S, Collier D, Kerwin RW, Pilowsky LS, Gill M, Zu WM, Thornton A (1993): Dopamine D4 receptor sub-types and response to clozapine. Lancet 341:116
377. Shelton RC, Weinberger DR (1986): X-ray computerized tomography studies in schizophrenia: A review and synthesis. Nasrallah HA, Weinberger DR (eds), The Neurology of Schizophrenia. Handbook of Schizophrenia. Amsterdam, Elsevier, vol 1, pp. 207-250
378. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR (1993): Molecular cloning and expression of a 5-hydroxytryptamine-7 serotonin receptor subtype. J Biol Chem 268:18200-18204
379. Sherman AD, Hegwood TS, Baruah S, Waziri R (1991): Deficient NMDA-mediated glutamate release from syn-aptosomes of schizophrenics. Biol Psychiatry 30:1191-1198
380. Simon H, Taghzouti K, Gozlan H, Studier JM, Louilot A, Herve D, Glowinski J, Tassin JP, LeMoal M (1988): Lesion of dopaminergic terminals in the amygdala produces enhanced locomotor response to D-amphetamine and opposite changes in dopaminergic activity in prefrontal cortex and nucleus accumbens. Brain Res 447:335-340
381. Simpson MDC, Slater P, Deakin JFW, Royston MC, Skan WJ (1990): Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 107:211-215
382. Simpson MDC, Slater P, Royston MC, Deakin JFW (1992): Alterations in phencyclidine and sigma binding sites in schizophrenic brains: Effects of disease process and neuroleptic medication. Schizophr Res 6:41-48
383. Singh MM, Kay SR (1979): Therapeutic antagonism between anticholinegic anti-Parkinsonian agents and neuroleptics in schizophrenia: Implications for a neuropharmaco-logical model. Neuropsychobiology 5:74-86
384. Sokoloff P, Andrieux M, Besancon R, Piion C, Martres MP, Giros B, Schwartz JC (1992a): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: Comparison with D2 receptor. Eur J Pharmacol 225:331-337
385. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990), Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151
386. Sokoloff P, Martres MP, Giros B, Bouthenet ML, Schwartz JC (1992b): The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol 43:659-666
387. Sommermeyer H, Dompert WU, Glaser T (1993): Signalling via rat dopamine D2 receptors expressed in mouse fibroblast is not influenced by compounds binding to the sigma sites of these cells. Cell Signalling 5:747-752
388. Spokes EGS, Garret NJ, Rossor MN, Iversen LL (1980): Distribution of GABA in post-mortem brain tissue from control, psychotic, and Huntington's chorea subjects. J Neurol Science 48:303-313
389. Squires RF, Lajtha A, Saederup E, Palkovits M (1993): Reduced (3H)flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: Is selective loss of glutamatergic neurons associated with major psychoses? Neurochem Res 18:219-223
390. Starle L, Collin AK, Ungerstedt U (1990): Effect of halothane anaesthesia on extracellular levels of dopamine, dihy-droxyphenylacetic acid, homovanillic acid in rat striatum: A microdialysis study. Naunyn-Schmiedeberg's Arch Pharmacol 342:136-140
391. Stille G, Lauener H, Eichenberger E (1971): The pharmacology of 8-chloro-ll-(4-methyl-l-piperazinyl)-5H-dibenzo [b, e] [1,4] diazepine (Clozapine). II Farmaco 26:603-625
392. Stockmeier CA, DiCarlo J], Zhang Y, Thompson P, Meltzer HY (1993): Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266: 1374-1384
393. Stoof JC, Kebabian JW (1981): Opposing roles for Di and D2 dopamine receptors in efflux of cyclic AMP from neostriatum. Nature 294:366-368
394. Stormann TM, Gdula DC, Weiner DM, Brann MR (1990): Molecular cloning and expression of a dopamine D2 receptor from human retina. Mol Pharmacol 37:1-6
395. Stowe ZN, Nemeroff CB (1993): Non-dopaminergic mechanisms relevant to antipsychotic activity. In Brunello N, Mendlewicz J, Racagni G (eds), New Generation of Antipsychotic Drugs: Novel Mechanisms of Action. Int Acad Biomed Res, vol 4, Basel, Karger, pp 15-26
396. Strader C, Sigal IS, Dixon RAF (1989): Structural basis of beta-adrenergic receptor function. FASEB J 3:1825-1832
397. 4 receptors: Curiouser and curiouser. Trends Pharmacol Sci 15:317-319
398. Suddath RL, Casanova MF, Goldberg TE, Daniel DG, Kel soe JR, Weinberger DR (1989): Temporal-lobe pathology in schizophrenia: A quantitative magnetic-resonance imaging study. Am J Psychiatry 146:464-472
399. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR (1990): Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 322:789-794
400. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, George SR, Torchia J, Van Tol HHM, Niznik HB (1991): Cloning of the gene for a human dopamine D5 receptor with a higher affinity for dopamine than Di. Nature 350:614-619
401. Sunahara RK, Niznik HB, Weiner DM, Stormann TM, Brann MR, Kennedy JL, Gelemter JE, Rozmahel R, Yang Y, Israel Y, Seeman P, O'Dowd BF (1990): Human dopamine Di receptor encoded by an intronless gene on chromosome 5. Nature 347:80-83
402. Surmeier DJ, Reiner A, Levine MS, Ariiano MA (1993): Are neostriatal dopamine receptors co-localized? Trends Neu-rosci 8:299-305
403. Swahn C-G (1990): Determination of N-acetyl-L-aspartic acid in human cerebrospinal fluid by gas chromatography-mass spectrometry. J Neurochem 54:1584-1588
404. Tamminga CA, Gerlach J (1987): New neuroleptics and experimental antipsychotics in schizophrenia. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York, Raven Press, pp. 1129-1140
405. Tatetsu S (1964): A contribution to the morphological background of schizophrenia: With special reference to the findings in the telencephalon. Acta Neuropathol (Berl) 3:558
406. Tiberi M, Jarvie KR, Silvia C, Falardeau P, Gingrich JA, Godi-not N, Bertrand L, Yang-Feng TL, Fremeau RT, Caron MG (1991): Cloning, molecular characterization and chromosomal assignment of a gene encoding a novel Di dopamine receptor subtype: Differential expression pattern in rat brain compared to Dia receptor. Proc Natl Acad Sci USA 88:7491-7495
407. Tork I (1991): Anatomy of the serotonergic system. Ann NY Acad Sci 600:9-34
408. Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mit-sushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N, Ogawa A (1988): Neurotransmitter receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121-137
409. Uhl GR, Kuhar MJ (1984): Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature 309:350-352
410. Uhl GR, Snyder SH (1977): Regional and subcellular distribution of brain neurotensin. Life Sci 19:1827-1832
411. Uphouse L, Andrade M, Caldarola-Pastusza M, Maswood S (1994): Hypothalamic infusion of the 5-HT2/1C agonist, DOI, prevents the inhibitory action of the 5-HTia agonist, 8-OH-DPAT, on lordosis behavior. Pharmacol Biochem Behav 47:467-470
412. Van Groen T, Wyss JM (1990): Extrinsic projections from area CA1 of the rat hippocampus: Olfactory, cortical, subcortical, and bilateral hippocampal formation projections. J Comp Neurol 302:515-528
413. Van Kammen DP (1977): Gamma aminobutyric acid (GABA) and the dopamine hypothesis of schizophrenia. Am J Psychiatry 134:138-143
414. Van Kammen DP, Antelman S (1984): Impaired noradrenergic transmission in schizophrenia? A mini review. Life Sci 34:1403-1413
415. Van Kammen DP, Peters J, van Kammen WB, Nugent A, Goetz KL, Yao J, Linnoila M (1989): CSF norepinephrine in schizophrenia is elevated prior the relapse after haloperidol withdrawal. Biol Psychiatry 26:176-188
416. Van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N (1991): Neuroleptic plasma levels. Schizophrenia Bull 17:197-215
417. Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991): Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614
418. Van Tol HHM, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1992): Multiple dopamine D4 receptor variants in the human population. Nature 358:149-152
419. Vartiainen H, Leinonen E, Putkonen A, Lang S, Hagert U, Tolvanen U (1993): A long-term study of remoxipride in chronic schizophrenic patients. Acta Psychiatr Scand 87:114-117
420. Vasse M, Protais P (1988): Increased grooming behavior is induced by apomorphine in mice treated with discriminant benzamide derivatives. Eur J Pharmacol 156: 1-11
421. Wadenberg ML, Ahlenius S, Svensson TH (1993): Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: Implications for the mechanism of action of clozapine. Psychopharmacology 110: 273-279
422. Walaas L (1981): Biochemical evidence for overlapping neo-cortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. Neuroscience 6:399-405
423. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC (1990): Sigma receptors: Biology and function. Pharmacol Rev 42:355-402
424. Walker JM, Matsumoto RR, Bowen WD, Gans DL, Jones KD, Walker FO (1988): Evidence for a role of haloperidol-sensitive sigma-opiate receptors in the motor effects of antipsychotic drugs. Neurology 38:961-965
425. Wallas I, Fonnum F (1980): Biochemical evidence for glutamate as a transmitter in hippocampal efferents to the basal forebrain and hypothalamus in the rat brain. Neuroscience 5:1,691-1,698
426. Walters JR, Bergstrom DA, Carlson JH, Chase TN, Braun AR (1987): Di dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 236:719-722
427. Wanibuchi F, Usuda S (1990): Synergistic effects between Di and D2 dopamine antagonists on catalepsy in rats. Psychopharmacology 102:339-342
428. Watling KJ, Beer MS, Stanton JA, Newberry NR (1990): Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervical ganglion of the rat. Eur J Pharmacol 182:465-472
429. Weick BG, Walters JR (1987): Effects of Di and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats. D1/D2 coactivation induces potentiated responses. Brain Res 405:234-246
430. Weinberger DR (1987): Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669
431. Weinberger DR, Berman KF, Illowsky B (1988): Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, III: A new cohort and evidence for a mono-aminergic mechanism. Arch Gen Psychiatry 45:609-615
432. Weinberger DR, Berman KF, Zee RF (1986): Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, I: Regional cerebral blood flow (rCBF) evidence. Arch Gen Psychiatry 43:114-125
433. Weinberger DR, DeLisi LE, Perman GP, Targum S, Wyatt RJ (1982): Computed tomography in schizophreniform disorder and other acute psychiatric disorders. Arch Gen Psychiatry 39:778-783
434. Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ (1979): Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 36:735-739
435. Weiner DM, Brann MR (1989): The distribution of a dopamine D2 receptor messenger-RNA in rat brain. FEBS Lett 253:207-213
436. Weiner DM, Levey AI, Brann MR (1990): Expression of muscarinic acetylcholine and dopamine receptor mRNA in rat basal ganglia. Proc Natl Acad Sci USA 87:7050-7054
437. Weiner DM, Levey AI, Sunahara RK, Niznik HB, O'Dowd BF, Seeman P, Brann MR (1991): Di and D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci USA 88:1859-1863
438. Weinshank RL, Adham N, Macchi M, Olsen MA, Brachek TA, Hartig PR (1991): Molecular cloning and characterization of a high affinity dopamine receptor (Dibeta) and its pseudogene. J Biol Chem 266:22427-22435
439. Widerlov E, Lindstrom LH, Bresev G, Manberg PJ, Nemeroff CB, Breese GR, Kizer JS, Prange AJ Jr (1982): Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: Normalization after neuroleptic treatment. Am J Psychiatry 139:1122-1126
440. Wiley JL, Porter JH (1992): Serotonergic drugs do not substitute for clozapine in clozapine-trained rats in a two-lever drug discrimination procedure. Pharmacol Biochem Be-hav 43:961-965
441. Williams AO, Reveley MA, Kolakowska T, Ardem M, Madel-brote BM (1985): Schizophrenia with good and poor outcome. II. Cerebral ventricular size and its clinical significance. Br J Psychiatry 146:239-246
442. Williams TG, Murtaugh MP, Beitz AJ (1990): The effects of acute haloperidol treatment on brain proneurotensin mRNA: In situ hybridization analysis using a novel fluorescence detection procedure. Mol Brain Res 7:347-358
443. Wilmot CA, Szczepanik AM (1989): Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 487:288-298
444. Winblad B, Bucht G, Gottfries CG, Roos BE (1979): Monoamines and monoamine metabolites in brain from demented schizophrenics. Acta Psychiatr Scand 60:17-28
445. Wolf S, Hyde TM, Weinberger DR (1993): Neurobiology of schizophrenia. Curr Opinion Neurol Neurosurg 6:86-92
446. Zhang J, Chiodo LA, Freeman AS (1992a): Electrophysiolog-ical effects of MK-801 on rat nigrostriatal and mesoaccum-bal dopaminergic neurons. Brain Res 590:153-163
447. Zhang J, Chiodo LA, Freeman AS (1993): Further characterization of the effects of BMY14802 on dopamine neuronal activity. Synapse 15:276-284
448. Zhang J, Chiodo LA, Wettstein JG, Junien J-L, Freeman AS (1992b): Acute effects of sigma ligands on the elec-trophysiological activity of rat nigrostriatal and mesoac-cumbal dopaminergic neurons. Synapse 11:267-278
449. Zhou QY, Grandy DR, Thambi L, Kushner JA, Van Tol HHM, Cone R, Pribnow D, Salon J, Bunzow JR, Civelli O (1990): Cloning and expression of human and rat Di dopamine receptors. Nature 347:76-80